As I recall, we held back on submitting the BTD fo
Post# of 148268
(Total Views: 498)
Posted On: 01/06/2022 6:13:29 PM
Re: generactor #114046
As I recall, we held back on submitting the BTD for mTNBC with brain metastasis because we wanted to see how the FDA responded to the first BTD submittal. This may be more of a question for Ohm, but I wonder if sacituzumab can penetrate the brain barrier.
Quote:
meaning leronlimab hasn't shown a substantial improvement over the approved SOC, sacituzumab
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
My comments are just my opinions and should NOT be taken as investment advice.
Scroll down for more posts ▼